Prostate specific antigen through the years

Archivio Italiano di Urologia e Andrologia

Volumn 81, Issue 4, 2009, Pages 195-198

  Kouriefs, Chryssanthos ^a   Sahoyl, Mukhtar ^a   Grange, Philippe ^a   Muir, Gordon ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

EPCA; History; PCA3; Prostate; PSA

Indexed keywords

EARLY PROSTATE CANCER ANTIGEN; ENZYME PRECURSOR; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

BRACHYTHERAPY; CANCER SCREENING; CANCER STAGING; FOLLOW UP; HUMAN; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVIEW; SEMEN ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

HISTORY, 20TH CENTURY; HUMANS; JAPAN; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 76149098203     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6.630 men. J Urol 1994; 151:1283-90.
2. Hara M, Inoue T, Koyanagi Y, Yamazaki H, Fukuyama T. lmmunoelectrophoretic studies of the protein components in human seminal plasma (especially its specific component). (Forensic immunological study of body fluids and secretions. VI). Nihon Hoigaku Zasshi 1969; 23:117-22.
3. Graves HC, Sensabaugh GF, Blake ET. Postcoital detection of a male-specific semen protein. Application to the investigation of rape. N Engl J Med 1985; 312:338-43.
4. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17:159-63.
5. Wang MC, Papsidero LD, Chu TM. Prostate-specific antigen, p30, gamma-seminoprotein, and E1. Prostate 1994; 24:107-10.
6. Ablin RJ, Bronson P, Soanes WA, Witebsky E. Tissue- and species-specific antigens of normal human prostatic tissue. J Immunol 1970; 104:1329-39.
7. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-spedfic antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317:909-16.
8. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145:907-23.
9. Marberger M, Adolfsson J, Borkowski A, Fitzpatrick J, Kirk D, Prezioso D, Rabaça C, Solsona E, Teillac P. The clinical implications of the prostate cancer prevention trial. BJU Int 2003; 92:667-71.
10. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270:860-4.
11. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279:1542-7.
12. Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, Hudson P, Jackson CL, Romas NA, Patterson L, Cook TJ, Waldstreicher J. Treatment with finasteride preserves usefulness of prostate-spedfic antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998; 52:195.
13. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol 1999; 162:1301-6.